Hydroxyurea (HU)

DRUG4 trials

Sponsors

Incyte Corporation, Bionoxx Inc., Ochuko Orherhe

Conditions

Polycythemia VeraSickle Cell DiseaseTreatment-Refractory Solid Tumors

Phase 1

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Not yet recruitingNCT07170592

Bionoxx Inc.Treatment-Refractory Solid Tumors

Start: 2027-01-01End: 2030-12-01Target: 24Updated: 2026-08-26

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

RecruitingNCT07190833

Bionoxx Inc.Treatment-Refractory Solid Tumors

Start: 2026-03-09End: 2030-12-01Target: 27Updated: 2026-08-26

Phase 3

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

CompletedNCT01632904

Incyte CorporationPolycythemia Vera

Start: 2012-06-30End: 2016-05-31Updated: 2017-11-14

Unknown Phase

Hydroxyurea Optimisation in Sickle Cell Disease

Not yet recruitingNCT07543289

Ochuko OrherheSickle Cell Disease

Start: 2026-05-08End: 2027-03-01Target: 100Updated: 2026-04-30

Related Papers

Ruxolitinib safety experience in the polycythemia vera clinical trial program.

Journal of Clinical Oncology2015-05-20